Objective: The objective of this analysis was to provide a comprehensive analysis of safety data for adjunctive brivaracetam (BRV), an antiepileptic drug (AED) of the racetam class, for treatment of focal seizures in patients with epilepsy. Methods: Data were pooled from two phase II, placebo-controlled, double-blind, dose-ranging trials (N01114 [ClinicalTrials.gov: NCT00175929], N01193 [NCT00175825]) and three phase III, placebo-controlled, doubleblind, 12-week trials (N01252 [NCT00490035], N01253 [NCT00464269], and N01358 [NCT01261325]) in patients aged ≥16 years with focal seizures, as well as a phase III, placebo-controlled, double-blind, 16-week trial in patients aged ≥16 years with focal or generalized epilepsy (N01254 [NCT00504881]). Data are presented for the approved therapeutic dose range of 50-200 mg/day. Data for BRV administered intravenously (25-150 mg doses) were pooled separately from one phase III trial (N01258 NCT01405508]) and two clinical pharmacology trials (N01256 [Part B] [UCB Pharma, data on file]; EP0007 [NCT01796899]). Adverse events (AEs) of interest were summarized in relevant categories. Results: The safety pool comprised 1957 patients: 1271 receiving adjunctive BRV and 686 receiving placebo.
Introduction
Brivaracetam (BRV), a member of the racetam class, is a selective high-affinity ligand for synaptic vesicle protein 2A (SV2A) [1] . Brivaracetam has been approved as adjunctive therapy and monotherapy for focal (partial-onset) seizures in patients (≥4 years of age) with epilepsy in the United States (US), and as adjunctive therapy for focal seizures in patients (≥ 4 years of age) with epilepsy in the European Union (EU). The primary data that supported the adjunctive and monotherapy indications were derived from three phase III, placebo-controlled, double-blind, fixed-dose trials in patients ≥ 16 years of age with focal seizures uncontrolled by one or two antiepileptic drugs (AEDs) (N01252 [ClinicalTrials.gov: NCT00490035] [2] , N01253
[NCT00464269] [3] , and N01358 [NCT01261325] [4] ). Pooled efficacy and safety data from these trials have been published [5] .
The current summary provides an in-depth, comprehensive analysis of pooled safety data from two phase II dose-ranging trials [6, 7] , three fixed-dose phase III trials [2] [3] [4] , and a flexible-dose phase III trial of adjunctive BRV [8] , including further details on treatment-emergent adverse events (TEAEs) of interest that were not included in earlier publications. This extra information will be useful to help prescribers make informed clinical decisions for patients with epilepsy. In one of the phase II dose-ranging trials, patients received BRV 50 or 150 mg/day for 7 weeks after a 3-week titration period [7] ; in the other trial, patients received BRV 5-50 mg/day without up-titration for 7 weeks [6] . In the three fixed-dose phase III trials, patients received BRV 5-200 mg/day without up-titration for 12 weeks [2] [3] [4] . In the phase III flexible-dose trial, patients initiated BRV at 20 mg/day and increased, as needed, to 150 mg/day during an 8-week dose-finding period, which was followed by an 8-week stable-dose maintenance period [8] . Data presented in this analysis include only the approved therapeutic dose range of 50-200 mg/day. Additionally, safety data for BRV administered intravenously (IV; approved by the Food and Drug Administration in the US for patients aged ≥ 16 years; for EU, see above) are presented, pooled from two clinical pharmacology trials: N01256 (Part B) (UCB Pharma, data on file) and EP0007 (NCT01796899) [9] , and a phase III trial: N01258 (NCT01405508) [10] .
Methods

Trials and populations
Safety pool
The safety pool consisted of patients who received at least one dose of BRV 50-200 mg/day or placebo in the placebo-controlled, doubleblind, phase II dose-ranging trials (N01114 [NCT00175929] [7] , N01193 [NCT00175825] [6] ), the placebo-controlled, double-blind, fixed-dose, phase III trials in patients ≥ 16 years of age with focal seizures (N01252 [NCT00490035] [2] , N01253 [NCT00464269] [3] , and N01358 [NCT01261325] [4] ), or the placebo-controlled, double-blind, flexible-dose trial in patients ≥ 16 years of age with epilepsy (N01254 [NCT00504881] [8] ). It should be noted that trial N01254 included 49 patients with generalized epilepsy. The trials were approved by an appropriate ethical review board and conducted in accordance with the relevant regulatory requirements, including the International Conference on Harmonisation/Good Clinical Practice requirements. Patients taking concomitant levetiracetam (LEV) were included in the safety pool. Concomitant LEV use was restricted to a maximum of 20% of patients in trials N01252, N01253, and N01254 and was not permitted in trial N01358.
Elderly population
The most common TEAEs for patients treated with BRV 50-200 mg/day in the safety pool were summarized by age at trial entry (17-b65 years, ≥65 years).
IV safety pool
The IV safety pool included pooled data from the clinical pharmacology studies N01256 (Part B) and EP0007 (NCT01796899) [9] , and the phase III, randomized, four-arm, parallel-group trial N01258 (NCT01405508) [10] . In the IV safety pool, 104 patients with epilepsy received IV BRV 100 mg twice daily (up to nine doses) as infusion (administered over 15 min) or bolus (administered over 2 min), and 49 healthy participants received IV BRV 25-150 mg (two or five single doses as infusion administered over 15 min or bolus administered over 30 s to 3 min, depending on dose).
Definitions of adverse events of interest
Adverse events (AEs) were coded using the Medical Dictionary for Regulatory Activities (MedDRA) Version 15.0 (www.meddra.org, March 2012). Details on TEAEs are presented for the System Organ Classes (SOCs) 'Nervous system disorders', 'Psychiatric disorders', 'Metabolism and nutrition disorders', and 'Injury, poisoning and procedural complications'. Further AEs of interest relative to BRV were identified by a comprehensive medical review of the MedDRA dictionary of preferred terms (PTs) and were categorized as follows: nonpsychotic behavioral disorders, hostility and aggression, depression or anxiety, suicidality, psychosis, cognitive impairment, hypersensitivity reactions, severe cutaneous adverse reactions, renal effects, hepatic effects, drug abuse potential, hematology (blood dyscrasias), and seizure changes. Preferred terms could be included in more than one category. A retrospective search of the pooled data was made using the PTs identified for each category.
Hepatic enzyme abnormalities were defined based on Hy's Law as either or both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) N 3×, N5×, N10×, or N20× the upper limit of the normal range (ULN); either AST or ALT N3 × ULN with concurrent total bilirubin ≥1.5× or ≥2× ULN; and either AST or ALT N3× ULN with concurrent alkaline phosphatase b2 × ULN and concurrent total bilirubin ≥2× ULN.
No statistical comparisons were conducted, based on common practice for assessing safety and tolerability data, and the post hoc nature of the analysis.
Results
Patients
The safety pool (N = 1957) comprised 1271 patients exposed to BRV ≥50 mg/day and 686 patients exposed to placebo. A total of 334/360 (92.8%), 403/440 (91.6%), 214/221 (96.8%), and 225/250 (90.0%) patients completed the trials in the BRV 50, 100, 150, and 200 mg/day groups, respectively, and 639/686 (93.1%) patients completed the trials in the placebo group (Table 1) In the IV safety pool, 103/104 (99.0%) patients and all healthy participants (49/49; 100%) receiving IV BRV completed the trials. One patient (1/104 [1.0%]) receiving 100 mg IV BRV discontinued because of an AE (anxiety) [10] .
Safety and tolerability
All treatment-emergent adverse events
In the safety pool, the overall incidence of TEAEs was 66.9% with BRV and 62.8% with placebo ( Table 2 ). The most frequently reported TEAEs were somnolence, headache, dizziness, and fatigue. Somnolence, dizziness, and fatigue were reported more frequently with BRV than placebo. No apparent relationships were identified between BRV dose and the incidence of individual TEAEs across the therapeutic range.
In the subgroup of patients who were taking concomitant LEV at trial entry (n = 231), the most frequently reported TEAEs were similar to those in the whole safety pool. Treatment-emergent adverse events reported by ≥ 5% of BRV-treated patients taking concomitant LEV were headache (BRV: 22 
Nervous system disorders
Most TEAEs reported with BRV were in the MedDRA SOC 'Nervous system disorders'. The most frequently reported nervous system disorder-related TEAEs (≥ 2% of BRV-treated patients) were somnolence, headache, dizziness, and convulsion ( Table 3 ). Few of the TEAEs associated with nervous system disorders in BRV-treated patients were serious or led to discontinuation ( Table 3 ).
Psychiatric disorders
Treatment-emergent adverse events in the MedDRA SOC 'Psychiatric disorders' (which includes terms related to nonpsychotic behavioral disorders, hostility or aggression, depression or anxiety, suicidality, psychosis, and cognitive impairment) were reported in 11.3% of patients receiving BRV and 8.2% of patients receiving placebo (Table 4 ). In this category, TEAEs leading to discontinuation were reported in 16/1271 (1.3%) patients receiving BRV and 8/686 (1.2%) patients receiving placebo. Individual psychiatric TEAEs leading to discontinuation of BRV were anxiety (BRV: 0.2% vs. placebo: 0.3%), depression (BRV: 0.2% vs. placebo: 0.3%), insomnia (BRV: 0.2% vs. placebo: 0%), psychotic disorder (BRV: 0.2% vs. placebo: 0.1%), abnormal behavior (BRV: b0.1% vs. placebo: 0%), adjustment disorder (BRV: b0.1% vs. placebo: 0%), aggression (BRV: b0.1% vs. placebo: 0%), agitation (BRV: b 0.1% vs. placebo: 0%), conversion disorder (BRV: b0.1% vs. placebo: 0%), restlessness (BRV: b0.1% vs. placebo: 0%), and stress (BRV: b0.1% vs. placebo: 0%).
Behavioral disorders, hostility and aggression, depression or anxiety, suicidality, and psychosis
Treatment-emergent adverse events associated with behavioral disorders (based on the medical review of the MedDRA PTs) were reported in 4.0% of BRV-treated patients and 2.5% of patients receiving placebo ( Table 4 ). The most common TEAE in this category (≥1% of BRV-treated patients) was irritability (BRV: 2.7% vs. placebo: 1.5%). Anger, aggression, and agitation were each reported by ≤ 1% of patients receiving BRV. Two patients reported serious TEAEs associated with behavioral disorders; both had adjustment disorder (one mild/moderate, one severe) that was not considered related to trial treatment; one patient discontinued, and the other completed the trial. Behavioral TEAEs leading to discontinuation were irritability (n = 3), abnormal behavior (n = 1), adjustment disorder (n = 1), aggression (n = 1), and agitation (n = 1) in patients receiving BRV and anger (n = 1) in patients receiving placebo ( Table 4 ).
The specific TEAEs associated with "hostility or aggression" in ≥0.3% of BRV-treated patients (agitation, aggression, irritability, and laceration) overlapped with those identified as "behavioral disorders" (≥0.3% of BRV-treated patients: agitation, aggression, and irritability).
Among patients receiving BRV and placebo, depression was reported by 2.0% and 1.2%, respectively, and anxiety was reported by 1.5% and 1.0%, respectively (Table 4 ). Treatment-emergent adverse events associated with depression or anxiety leading to discontinuation were anxiety (n = 3), depression (n = 3), and agitation (n = 1) in patients receiving BRV and anxiety (n = 2), depression (n = 2), and panic attack (n = 1) in patients receiving placebo. The most common TEAE associated with suicidality was depression (see above). Suicidal ideation was reported in six patients, three (0.2%) receiving BRV versus three (0.4%) receiving placebo. No patients attempted or completed suicide.
The most common TEAE associated with psychosis was psychotic disorder, which was reported in three patients (0.2%) receiving BRV and two patients (0.3%) receiving placebo. Psychotic disorder was reported as serious in two BRV-treated patients; both were female and neither had a prior history of psychosis. Brivaracetam treatment was discontinued for both patients, and both received antipsychotic medication. One patient (BRV 100 mg/day, concomitant AEDs: clobazam, oxcarbazepine) recovered three days after onset; the second patient (BRV 50 mg/day, concomitant AEDs: lamotrigine, zonisamide) was diagnosed with medication-induced psychosis that was ongoing at follow-up (21 days after discontinuing BRV). In addition, one patient receiving BRV 50 mg/day reported illusion (perceptual disturbance), which resolved with no change in BRV dosage; one patient receiving BRV 100 mg/day reported auditory hallucination, which resolved on the same day with no change in BRV dosage; and one patient receiving BRV 50 mg/day reported visual hallucination, which was ongoing at database lock. One patient receiving placebo reported epileptic psychosis (postictal psychosis), and another patient on placebo reported hallucination.
Cognitive impairment
At least one TEAE associated with cognitive impairment was reported by 41/1271 (3.2%) patients receiving BRV and 20/686 (2.9%) patients receiving placebo. The most commonly reported TEAE in this category was memory impairment, reported by 14/1271 (1.1%) patients receiving BRV versus 9/686 (1.3%) patients receiving placebo. There was no apparent relationship between BRV dose and incidence of TEAEs associated with cognitive impairment across the therapeutic range.
One TEAE associated with cognitive impairment was serious: a patient in the BRV 50 mg/day group had amnesia concurrent with a temporary increase in seizure frequency (reported as convulsion); BRV was continued and both events resolved. Five patients discontinued due to TEAEs associated with cognitive impairment: two patients with memory impairment in the BRV 50 mg/day and 100 mg/day group, one patient with amnesia in the BRV 100 mg/day group, one patient with mental impairment in the BRV 100 mg/day group, and one patient with psychomotor skill impairment in the placebo group. 
Severe cutaneous adverse reactions
The only TEAE associated with severe cutaneous adverse reactions was erythema multiforme, which was reported in one patient in the BRV 100 mg/day group.
Renal effects
There were no reports of TEAEs associated with renal impairment in BRV-treated patients. In the placebo group, one (0.1%) patient reported a TEAE associated with renal impairment (azotemia).
Hepatic effects
Similar proportions of BRV-and placebo-treated patients reported TEAEs associated with hepatotoxicity (24/1271 [1.9%] vs. 11/686 [1.6%], respectively). The incidence of TEAEs associated with hepatotoxicity was similar across BRV treatment groups. There were no reports of drug-induced liver injury, and no patients on BRV met Hy's Law criteria (see Section 2, Methods). The most commonly reported TEAE associated with hepatotoxicity was increased gamma-glutamyltransferase (GGT) (14/1271 [1.1%] patients receiving BRV vs. 7/686 [1.0%] patients receiving placebo). There were no reports of serious TEAEs associated with hepatotoxicity. A TEAE associated with hepatotoxicity (increased hepatic enzymes) led to discontinuation in one patient (BRV 200 mg/day); this patient also had other TEAEs that led to discontinuation (insomnia, hypertension, tachycardia). The patient's ALT increased from 62 U/L at baseline to 89 U/L on day 29, AST from 38 to 59 U/L, alkaline phosphatase from 84 to 137 U/L, and GGT from 89 to 160 U/L. Three weeks later, ALT, AST, and alkaline phosphatase levels had returned to within the normal range (35, 22 , and 81 U/L, respectively), and GGT was close to baseline level (96 U/L).
Cardiac arrhythmias
Two patients (0.2%) receiving BRV and no patients on placebo had a TEAE of QT prolongation. The events were not serious and did not lead to discontinuation. There were no occurrences of torsades de pointes. 
Hematology
Treatment-emergent adverse events associated with blood dyscrasias were uncommon ( Table 5 ). The most common TEAEs in BRV-treated patients were neutropenia, decreased platelet count, and decreased neutrophil count, which were reported in 9/1271 (0.7%), 4/1271 (0.3%), and 4/1271 (0.3%) patients receiving BRV versus 1/686 (0.1%), 0/686 (0%), and 2/686 (0.3%) patients receiving placebo, respectively. The only TEAE that was reported as serious was neutropenia in one patient on BRV 100 mg/day. Treatment-emergent adverse events associated with blood dyscrasias leading to discontinuation were neutropenia (n = 3) and decreased neutrophil count (n = 1) in patients receiving BRV and neutropenia (n = 1) and thrombocytopenia (n = 1) in patients receiving placebo.
Clinical chemistry
Overall, clinical chemistry values tended to be normal at baseline and remained normal throughout the trials. The number of patients who shifted from normal values at baseline to abnormally low or high values at last visit was small for all parameters across all treatment groups. None of these shifts were considered to be clinically significant ( Table 6 ).
Metabolism and nutrition disorders
Incidence of TEAEs in the SOC 'Metabolism and nutrition disorders' were uncommon, with only decreased appetite, hyponatremia, and hypocholesterolemia reported by ≥0.5% of patients receiving BRV. Decreased appetite was reported by 27/1271 (2.1%) patients receiving BRV versus 7/686 (1.0%) patients receiving placebo, hyponatremia was reported by 11/1271 (0.9%) patients receiving BRV versus 2/686 . All other serious TEAEs associated with seizure exacerbation were reported for ≤1 patient in any treatment group. The most common TEAE associated with seizure exacerbation leading to discontinuation was convulsion (BRV: 9/1271 [0.7%] vs. placebo: 4/686 [0.6%]). All other TEAEs associated with seizure exacerbation led to discontinuation of the study drug in ≤1 patient in any treatment group.
Falls and injuries
Falls were reported by 15/1271 (1.2%) BRV-treated patients and 7/686 (1.0%) placebo patients. Accidental injuries (SOC 'Injury, poisoning and procedural complications') were reported by 93/1271 (7.3%) BRV-treated patients and 55/686 (8.0%) placebo patients.
Deaths
In the safety pool, three patients in the BRV 50-200 mg/day group and one patient in the placebo group died, all of these patients died during the fixed-dose phase III trials. A 19-year-old man (200 mg/day) with a history of status epilepticus experienced sudden unexpected death in epilepsy (SUDEP). A 34-year-old man (200 mg/day) experienced a typical focal seizure and was found unresponsive 5 h later; a specific cause of death was not recorded. A 21-year-old woman (50 mg/day) was found unresponsive in her bed; cause of death was recorded as brain hypoxia. All three deaths met the criteria for SUDEP. A 69-year-old patient receiving placebo died because of sepsis.
Safety in elderly patients
In the small population of patients aged ≥65 years, the most common TEAEs (≥5%) in patients receiving BRV 50-200 mg/day (n = 25) versus placebo (n = 11) were headache (12.0% vs. 18.2%), paresthesia (12.0% vs. 0%), somnolence (12.0% vs. 36.4%), constipation (8.0% vs. 0%), convulsion (8.0% vs. 0%), dizziness (8.0% vs. 9.1%), hyponatremia (8.0% vs. 0%), and insomnia (8.0% vs. 9.1%). The two patients with hyponatremia were a 72-year-old man concomitantly taking oxcarbazepine, zonisamide, and nitroxoline who had hyponatremia for 15 days before it resolved and a 65-year-old woman concomitantly taking oxcarbazepine, irbesartan, omeprazole, and duloxetine who had intermittent hyponatremia for 32 days before it resolved; these TEAEs were investigator-reported, and sodium values are not available. In comparison, TEAEs reported by ≥5% of patients aged 17-b65 years receiving BRV 50-200 mg/day (n = 1234) versus placebo (n = 664) were somnolence (13.2% vs. 7.5%), headache (10.3% vs. 11.6%), dizziness (10.0% vs. 7.1%), and fatigue (8.2% vs. 4.2%).
Safety of IV formulation
In patients (n = 104) and healthy participants (n = 49) combined who received IV BRV (25-150 mg doses), the TEAEs that occurred in ≥ 3% of participants overall were somnolence (30.1%), dizziness (15.7%), fatigue (15.0%), headache (7.2%), dysgeusia (6.5%), euphoric mood (3.9%), feeling drunk (3.9%), and infusion site pain (3.3%). Dysgeusia and infusion site pain were not reported in the three phase III trials using the BRV oral tablet formulation. Most TEAEs were mild or moderate; one patient had severe TEAEs of nausea and vertigo. No serious TEAEs were reported in patients and healthy participants who received IV BRV. At least one injection-related TEAE occurred in 11/104 (10.6%) patients receiving IV BRV. The only injection-related TEAEs that occurred in ≥2% of patients were infusion-site pain (5/104 [4.8%]) and injection-site extravasation (3/104 [2.9%]).
Discussion
We present a comprehensive analysis of pooled safety data from patients who received therapeutic doses (50-200 mg/day) of adjunctive BRV in two phase II, dose-ranging trials, three phase III, 12-week, fixed-dose trials, and a phase III, 16-week flexible-dose trial. In most of these trials, the therapeutic dose was administered without uptitration. Overall, the findings suggest a favorable tolerability profile for BRV. The pooled data for the small numbers of elderly patients and patients receiving IV BRV presented in this review, together with previously published reports, suggest no additional safety concerns for BRV in patients aged ≥65 years [11] or in patients receiving IV BRV [9, 10] .
Psychiatric and behavioral AEs are common in patients taking AEDs [12] . However, it is not clear whether this is due to some individuals being more prone to developing psychiatric AEs [13] . In the BRV safety pool, 11.3% of patients treated with BRV 50-200 mg/day (8.2% on placebo) reported psychiatric disorder-related TEAEs and 4.0% (2.5% on placebo) reported behavioral disorder-related TEAEs. Patients with epilepsy are at risk of developing psychiatric comorbidities, including psychotic disorders [14] . In the current analysis, there were rare reports of psychotic disorder (BRV 0.2% vs. placebo 0.3%) and epileptic psychosis (BRV 0% vs. placebo 0.1%). Two of the three cases of psychotic disorder in BRV-treated patients were serious and led to discontinuation of BRV.
There has been much focus on the potential for AEDs in general to increase the risk of suicidality in patients with drug-resistant epilepsy. In the BRV safety pool, there was no difference in rates of suicidal ideation between BRV-and placebo-treated patients, and there were no attempted or completed suicides. However, two completed suicides were reported in the open-label follow-up trials (N = 2051) [15] . One patient had received BRV for 10.6 months and had no recent dose changes, and the other had received BRV for 24.8 months, had no recent dose changes, and had started concomitant topiramate one month before death [15] .
Both BRV and LEV are thought to exert their primary antiepileptic effect by binding selectively to the SV2A protein, although it is hypothesized that they may have a differential interaction with SV2A [16] . Conventional AED mechanisms do not appear to contribute to BRV's antiepileptic properties, as they do for LEV [17] . It is not valid to directly compare the incidence of particular AEs between LEV and BRV, as the published safety profile of LEV [18] is based on the clinical development program that was conducted approximately two decades ago. Since that time, there have been changes in medical practice and increased awareness of the potential association of AEDs with psychiatric and behavioral AEs. Adverse events were classified in the LEV trials using the Coding Symbols for Thesaurus of Adverse Reaction Terms (FDA 1997), while BRV trials used the more recent MedDRA version 15.0 (www.meddra. org, March 2012). Furthermore, the pivotal LEV trials were conducted solely in Europe [19, 20] or the US [21] , while the pivotal BRV trials also recruited patients in Australia, Latin America, and Asia [5] . Given these caveats, the reported incidence of behavioral problems in LEV-treated patients with epilepsy was 13.5% (versus 6.0% with placebo) [18] , while in our analyses, TEAEs potentially associated with behavioral disorders occurred in 4.0% of BRV-treated patients (versus 2.5% with placebo). A few studies have reported changes in behavioral AEs following a switch from LEV to BRV. In a small open-label study, 27/29 (93.1%) patients who underwent an immediate switch from LEV to BRV reported clinically meaningful reductions in behavioral AEs, and 62.1% reported resolution of all behavioral AEs [22] . A postmarketing study reported a reduction in LEV-associated behavioral TEAEs in 20/35 (57.1%) patients who switched from LEV to BRV [23] . Nevertheless, patients who experienced behavioral AEs with LEV were more likely to report behavioral AEs with BRV. Another postmarketing study (n = 101) showed a low incidence of psychiatric AEs in patients who switched from LEV to BRV, or added BRV to their existing AED regimen [24] .
Many AEDs are known to cause hematological changes including thrombocytopenia, neutropenia, and anemia; however, the reported incidence of these changes for LEV is low [25] . Hyponatremia has been reported in some patients receiving LEV [26, 27] . In the BRV safety pool, the incidence of neutropenia was low in patients receiving BRV 50-200 mg/day (0.7%) and placebo (0.1%). Hyponatremia was reported as a TEAE in eleven BRV-treated patients versus two patients receiving placebo. Of these, five patients in the BRV group and both patients in the placebo group had hyponatremia that was considered treatmentrelated by the investigators. Some cases of hyponatremia occurred in patients ≥ 65 years of age (2/25 of elderly patients receiving BRV vs. 0/11 receiving placebo).
In the safety pool, two BRV-treated patients and no placebo-treated patients had a TEAE of QT prolongation. There were no occurrences of torsades de pointes. A thorough QT study in healthy participants demonstrated no effect of BRV on cardiac repolarization at both therapeutic (150 mg/day) and supratherapeutic (800 mg/day) doses, and suggested that no intensive cardiac monitoring was needed with BRV [28] .
Hypersensitivity reactions to AEDs may, albeit rarely, lead to treatment failure, morbidity, and mortality [29] . In the BRV safety pool, the incidence of rash and pruritus was low, and there were no reports of bronchospasm or angioedema (both described in the BRV prescribing information as hypersensitivity reactions for which patients should "seek immediate medical care") or of anaphylaxis [30] . In the literature, there have been single reports of bronchospasm (one day posttreatment with BRV) and angioedema (during long-term, open-label BRV treatment) in adults [30] . The first patient developed mild dyspnea and myalgia on the second day of treatment with BRV 20 mg/day. Brivaracetam was discontinued, and the patient received analgesia (metamizole). The following day, the patient experienced an episode of severe bronchospasm and went to an emergency department, where chest X-ray, electrocardiogram, and blood tests were normal. The patient was treated with bronchodilators and steroids, and the bronchospasm resolved. The second patient developed angioedema (Quincke's edema) after 239 days of BRV exposure while receiving BRV 50 mg/day and carbamazepine. Brivaracetam was continued at the same dose, and the TEAE resolved within five days after treatment with calcium gluconate and chlorpheniramine.
Euphoric mood and feeling drunk are regarded as possible indicators of a drug's abuse potential [31] . The incidences of these TEAEs were 0.2% and 0.3%, respectively in BRV-treated patients. Likewise, there were no reports of abuse, misuse, dependence, or withdrawal with BRV across the BRV clinical development program, and reports of hallucinations, stimulant-related events, dissociative events, mood disorders, and motor/cognitive impairment events were low (UCB Pharma, data on file). Findings from a randomized, double-blind, triple-dummy human abuse potential study in recreational users of central nervous system depressants with single therapeutic doses of BRV (50 mg) showed lower abuse potential on subjective scales than alprazolam, a Schedule IV drug [32] . Furthermore, BRV has a low risk of acute or chronic intoxication. In healthy participants, the maximum tolerated dose of BRV was 1000 mg for single intake [33] and 800 mg/day after repeated dosing over 2 weeks [34] . There are no data on single intakes exceeding 1400 mg but, at that dose, somnolence and dizziness are the most frequently reported AEs in healthy participants [33] . All AEs associated with overdose were related to accidental or intentional (suicide attempts) overdoses with other drugs (UCB Pharma, data on file).
All three deaths reported in BRV-treated patients in the fixed-dose phase III trials met the criteria for SUDEP [35] . Across the BRV longterm safety population (N = 2186), 12 cases of SUDEP have been identified, including nine cases of definite or probable SUDEP [15] . The SUDEP incidence rate (95% CI) per 1000 patient-years in this population was 2.2 (1.1-3.8) for definite, probable, or possible SUDEP, and 1.6 (0.7-3.1) for definite or probable SUDEP, and is therefore in accordance with the SUDEP incidence in the general population of patients with epilepsy (1.2 per 1000 patient-years) [36] .
The trials included in this safety review excluded patients that had medical or psychiatric conditions that, in the opinion of the investigator, could have jeopardized their health or compromised their ability to participate in the trial. The patients enrolled in these trials may therefore not be fully representative of the wider population of patients with epilepsy. A further limitation of this review is that only TEAEs reported during trials with durations of up to 16 weeks are included. Rare AEs, or those that develop with a latency longer than 16 weeks, may not have been uncovered. However, pooled safety data from N2000 adults with focal seizures who received BRV 50-200 mg/day in short-term and associated long-term follow-up trials with total exposure of 5300 patient-years did not identify any deterioration in safety and tolerability over time [15] . Very rare AEs may be identified only through extensive postmarketing exposure. Additionally, BRV was used as adjunctive treatment in the trials reviewed, and therefore, other AEDs may have contributed to the TEAEs.
Conclusions
This review provides a comprehensive summary of the safety profile of adjunctive BRV and will help prescribers make informed clinical decisions for patients with epilepsy.
Supplementary data to this article can be found online at https://doi. org/10.1016/j.yebeh.2019.106864.
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